|
16/12/2012 |
Bio-Rad to Acquire MorphoSys's Research and Diagnostic Antibody Business AbD Serotec |
 |
|
06/12/2012 |
MorphoSys Strengthens Patent Position on anti-CD38 Cancer Program MOR202 |
|
|
27/11/2012 |
MorphoSys and Lanthio Pharma Sign Technology Alliance on New Class of Therapeutic Peptides |
|
|
12/11/2012 |
MorphoSys Reports Successful Phase 1 Study of MOR103 Using a Subcutaneous Administration |
|
|
07/11/2012 |
MorphoSys Announces Expansion of Antibody Alliance |
|
|
07/11/2012 |
MorphoSys AG Reports Nine Months 2012 Results |
|
|
06/11/2012 |
MorphoSys to Present Clinical Data on MOR103 at 2012 American College for Rheumatology Annual Meeting |
|
|
05/11/2012 |
MorphoSys Announces Presentation of Preclinical Data on MOR202 and MOR208 at 2012 American Society of Hematology Annual Meeting |
|
|
05/11/2012 |
MorphoSys and Xencor Report Clinical Data for MOR208/XmAb5574 |
|
|
16/10/2012 |
AbD Serotec Licenses HuCAL Antibodies to DiaSorin for Use in Clinical Diagnostic Assays for Infectious Disease Testing |
|
|
05/10/2012 |
MorphoSys's Partner OncoMed Advances the HuCAL Antibody OMP-59R5 into Phase 1b/2 Clinical Trial in Pancreatic Cancer |
|
|
20/09/2012 |
MorphoSys's MOR103 Antibody Demonstrates Excellent Safety and Efficacy in Rheumatoid Arthritis Patients |
|
